Published in Magn Reson Med on March 01, 2010
A polymeric fastener can easily functionalize liposome surfaces with gadolinium for enhanced magnetic resonance imaging. ACS Nano (2013) 0.86
MRI estimation of gadolinium and albumin effects on water proton. Neuroimage (2010) 0.85
Human whole-blood (1)H2O longitudinal relaxation with normal and high-relaxivity contrast reagents: influence of trans-cell-membrane water exchange. Magn Reson Med (2013) 0.84
Specific and nonspecific interactions in ultraweak protein-protein associations revealed by solvent paramagnetic relaxation enhancements. J Am Chem Soc (2014) 0.82
Overcoming the low relaxivity of gadofosveset at high field with spin locking. Magn Reson Med (2011) 0.81
Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo. Magn Reson Med (2014) 0.78
The protein binding substance ibuprofen does not affect the T1 time or partition coefficient in contrast-enhanced cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 0.76
Relative sensitivities of DCE-MRI pharmacokinetic parameters to arterial input function (AIF) scaling. J Magn Reson (2016) 0.75
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc (2008) 1.98
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging (2009) 1.95
Primer on gadolinium chemistry. J Magn Reson Imaging (2009) 1.63
Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol (2009) 1.60
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem (2007) 1.58
Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology (2008) 1.48
Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol (2012) 1.45
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem (2007) 1.44
Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl (2010) 1.32
Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem (2004) 1.30
Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry (2008) 1.28
Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke (2010) 1.24
Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. Angew Chem Int Ed Engl (2008) 1.20
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed Engl (2005) 1.18
Enzyme-Activated Gd(3+) Magnetic Resonance Imaging Contrast Agents with a Prominent Receptor-Induced Magnetization Enhancement We thank Dr. Shrikumar Nair for helpful discussions. Angew Chem Int Ed Engl (2001) 1.16
Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model. Radiology (2010) 1.15
Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. Inorg Chem (2007) 1.13
Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. Bioconjug Chem (2012) 1.12
Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol (2013) 1.08
Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium. Circ Cardiovasc Imaging (2011) 1.07
Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol (2006) 1.05
High relaxivity magnetic resonance imaging contrast agents. Part 1. Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. Invest Radiol (2010) 1.05
Redox-activated manganese-based MR contrast agent. J Am Chem Soc (2013) 1.05
The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol (2008) 1.04
Pycup--a bifunctional, cage-like ligand for (64)Cu radiolabeling. Mol Pharm (2013) 1.03
High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol (2010) 1.03
Targeted probes for cardiovascular MRI. Future Med Chem (2010) 1.02
Gd(DOTAla): a single amino acid Gd-complex as a modular tool for high relaxivity MR contrast agent development. J Am Chem Soc (2012) 1.00
Molecular MRI of Thrombosis. Curr Cardiovasc Imaging Rep (2010) 1.00
Probing the water coordination of protein-targeted MRI contrast agents by pulsed ENDOR spectroscopy. Chemphyschem (2005) 0.99
Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm (2013) 0.98
Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation (2009) 0.97
Contrast agents for MRI: 30+ years and where are we going? J Biol Inorg Chem (2014) 0.94
Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity. Angew Chem Int Ed Engl (2011) 0.93
Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proof-of-concept study. Invest Radiol (2010) 0.90
Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. Inorg Chem (2013) 0.89
Molecular imaging of fibrin in a breast cancer xenograft mouse model. Invest Radiol (2012) 0.88
Discrete bimodal probes for thrombus imaging. J Am Chem Soc (2012) 0.87
Peptide optimization and conjugation strategies in the development of molecularly targeted magnetic resonance imaging contrast agents. Methods Mol Biol (2014) 0.86
Serum albumin targeted, pH-dependent magnetic resonance relaxation agents. Chemistry (2012) 0.85
When are two waters worse than one? Doubling the hydration number of a Gd-DTPA derivative decreases relaxivity. Chemistry (2005) 0.85
Determination of the hydration number of gadolinium(III) complexes by high-field pulsed 17O ENDOR spectroscopy. Chemphyschem (2006) 0.85
Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents. New J Chem (2010) 0.85
Structure-redox-relaxivity relationships for redox responsive manganese-based magnetic resonance imaging probes. Inorg Chem (2014) 0.84
Structure-relaxivity relationships of serum albumin targeted MRI probes based on a single amino acid Gd complex. J Med Chem (2013) 0.84
On the philosophy of optimizing contrast agents. An analysis of 1H NMRD profiles and ESR lineshapes of the Gd(III)complex MS-325+HSA. J Magn Reson (2004) 0.82
Direct measurement of the Mn(II) hydration state in metal complexes and metalloproteins through 17O NMR line widths. J Am Chem Soc (2013) 0.82
Three types of physical measurements needed to characterize iron oxide nanoparticles for MRI and MRA: magnetization, relaxometry, and light scattering. Acad Radiol (2002) 0.81
Activation and retention: a magnetic resonance probe for the detection of acute thrombosis. Angew Chem Int Ed Engl (2013) 0.80
Important considerations in the design of iron oxide nanoparticles as contrast agents for TI-weighted MRI and MRA. Acad Radiol (2002) 0.79
Probing the structure-relaxivity relationship of bis-hydrated Gd(DOTAla) derivatives. Inorg Chem (2015) 0.78
[Gd(CyPic3A)(H2O)2]-: a stable, bis(aquated) and high-relaxivity Gd(III) complex. Chem Commun (Camb) (2013) 0.78
Hexameric Mn(II) dendrimer as MRI contrast agent. Chemistry (2014) 0.78
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
Gd(DOTAlaP): exploring the boundaries of fast water exchange in gadolinium-based magnetic resonance imaging contrast agents. Inorg Chem (2014) 0.77
Magnetic resonance labeling of stem cells: is positive tracking a plus or a minus? JACC Cardiovasc Imaging (2009) 0.77
Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep (2009) 0.77
1H chemical shift magnetic resonance imaging probes with high sensitivity for multiplex imaging. Contrast Media Mol Imaging (2012) 0.77
Water-proton relaxation by a noncovalent albumin-binding gadolinium chelate: an NMRD study of a potential blood pool agent. Acad Radiol (2002) 0.76
Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem (2007) 0.76
Science to practice: how will myocardial inflammation be imaged with MR imaging? Radiology (2012) 0.75
Molecular MRI of the Cardiovascular System in the Post-NSF Era. Curr Cardiovasc Imaging Rep (2012) 0.75
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight (2017) 0.75